- Home
- VINP vs AUTL Comparison
VINP vs AUTL Comparison
Compare VINP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- AUTL
- Stock Information
- Founded
- VINP 2009
- AUTL 2014
- Country
- VINP Brazil
- AUTL United Kingdom
- Employees
- VINP N/A
- AUTL N/A
- Industry
- VINP Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VINP Finance
- AUTL Health Care
- Exchange
- VINP Nasdaq
- AUTL Nasdaq
- Market Cap
- VINP 641.7M
- AUTL 590.8M
- IPO Year
- VINP 2021
- AUTL 2018
- Fundamental
- Price
- VINP $10.27
- AUTL $2.17
- Analyst Decision
- VINP Strong Buy
- AUTL Strong Buy
- Analyst Count
- VINP 2
- AUTL 3
- Target Price
- VINP $13.50
- AUTL $10.20
- AVG Volume (30 Days)
- VINP 62.7K
- AUTL 1.1M
- Earning Date
- VINP 02-26-2025
- AUTL 03-13-2025
- Dividend Yield
- VINP 6.75%
- AUTL N/A
- EPS Growth
- VINP N/A
- AUTL N/A
- EPS
- VINP 0.60
- AUTL N/A
- Revenue
- VINP $88,217,697.00
- AUTL $10,091,000.00
- Revenue This Year
- VINP $17.23
- AUTL $851.83
- Revenue Next Year
- VINP $51.06
- AUTL $224.65
- P/E Ratio
- VINP $17.33
- AUTL N/A
- Revenue Growth
- VINP 9.03
- AUTL 82.71
- 52 Week Low
- VINP $9.01
- AUTL $2.07
- 52 Week High
- VINP $11.85
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- VINP 56.01
- AUTL 41.81
- Support Level
- VINP $10.00
- AUTL $2.11
- Resistance Level
- VINP $10.49
- AUTL $2.26
- Average True Range (ATR)
- VINP 0.22
- AUTL 0.12
- MACD
- VINP 0.07
- AUTL 0.01
- Stochastic Oscillator
- VINP 72.73
- AUTL 27.78
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.